Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727154 · ClinicalTrials.gov registry record
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
A clinical trial, sponsored by Dendreon.
- Terminated
- Registry status
- 139
- Enrollment target
NCT01727154: Clinical Trial study, sponsored by Dendreon.
NCT01727154 is a clinical trial that was terminated before completion, run by Dendreon. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01727154 was terminated before completion, sponsored by Dendreon.
- TERMINATED
- Registry status
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
Primary Outcome
The primary immune response analysis population will include all subjects who receive all 3 infusions of sipuleucel-T. The primary analysis will measure the percentage of subjects who exhibit any immune response at any post-treatment time point (6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T).
Interventions
- BIOLOGICAL Sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-07 |
Why NCT01727154 stopped before completion
NCT01727154 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Sipuleucel-T is the first listed.
NCT01727154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01727154 about?
NCT01727154 is a clinical study titled "Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T". The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
What is the current status of trial NCT01727154?
This trial is currently terminated. The enrollment target is 139 participants. The study started on 2012-10. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01727154?
The interventions under investigation include: Sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01727154?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia